Surfing the MASH Tsunami

Send us Fan Mail In a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). On November 4th-8th in Washington DC, as many as 10,000 attendees will convene in an effort to a...

Send us Fan Mail When AASLD announced that the 2021 event would be held as a purely virtual meeting, attendees and observers feared a loss of focus and the kind of amplifying energy that comes from being with colleagues. As this episode suggests, the breadth, quality and novelty of the meeting’s presentations generated exceptional positive energy even though colleagues could not meet in person thr...

Send us Fan Mail The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patien...

Send us Fan Mail The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patien...

Send us Fan Mail The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patien...

Send us Fan Mail The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patien...

Send us Fan Mail The 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. In this preview, Key Opinion Leaders Stephen Harrison, Jörn Schatt...

Send us Fan Mail One of the most intriguing presentations at the inaugural Innovations in NAFLD Care 2022 conference (INCBCN) came from physician, author and entrepreneur Dr. Marcus Ranney. In this conversation, Roger Green interviews Marcus on his experiences unique vision and the future of #biohacking. In this conversation From the Vault , Marcus discusses his own “journey of figuring out…how to...

Send us Fan Mail One critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient empowerment. In this conversation, Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss the use of FIB-4 as a front-line tool for primary care triage. Roger starts by notin...

Send us Fan Mail Patient empowerment can be an overlooked, yet critical success factor for putting a dent in Fatty Liver disease. In this conversation, the panelists investigate the economics of pathway design while identifying challenges and opportunities for effective solutions. The preceding dialogue has suggested that the guideline processes are too focused on opportunities for private sector...

Send us Fan Mail Patient empowerment can be an overlooked, yet critical success factor for putting a dent in Fatty Liver disease. This conversation details the involvement of three patient advocates in developing clinical care pathways and guidelines. Louise Campbell opens with a suggestion that companies focus mostly on purchasers of medication. This rarely includes patients, who are more often c...

Send us Fan Mail One critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient empowerment.  This conversation begins by carrying over thoughts on the future of digital therapeutics as a Pharma-supported patient wellness tool with advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain. Robert connects the idea with a...

Send us Fan Mail One critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient empowerment. In this conversation, Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patients’ perspectives and the extent they are considered in the clinical trial desi...

Send us Fan Mail One critical success factor for putting a dent in Fatty Liver disease – one we do not discuss very often on the podcast – is patient empowerment.  In this episode, Roger Green and Louise Campbell are joined by patient advocates Michael Betel, Wayne Eskridge and Robert Mitchell-Thain to discuss patients’ perspectives and their contributions to improving healthy liver outcomes. Loui...

Send us Fan Mail This conversation From the Vault comes from Season 3 Episode 13.4, part of NASH Tsunami’s coverage of the first NICE meeting on FibroScan.  Season 3, Episode 13 looks at the NICE Draft Guidance Evaluating FibroScan use in Community and Primary Care settings. This conversation focuses on underlying tensions between a methodology designed to assess big-ticket spending on critical mo...

Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) in the community. This final conversation centers around how to create and train on delivering meaningful test results to patients.  Roger Green begins with his note that in recent NASH Tsunami episod...

Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) in the community. This conversation begins with Will Alazawi concluding his comments on the link between liver outcomes and socioeconomic status. The group then explores a range of factors contributin...

Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) in the community. Professor Ian Rowe and Dr Kathryn Jack discuss navigating a scarcity of relevant data for evaluating pathway development alongside Surfers Roger Green and Louise Campbell.  Roger pro...

Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) in the community. In this conversation, Roger Green and Louise Campbell are joined by Dr Kathryn Jack and Professor Ian Rowe to discuss the dynamic challenges of using FibroScan and other noninvasive...

Send us Fan Mail Amidst a shifting diagnostic pathway, the UK’s National Institute for Health and Care Excellence (NICE) reconsiders its position on vibration controlled transient elastography (VCTE) in the community. In this episode, Roger Green and Louise Campbell are joined by Dr Kathryn Jack and Professors Ian Rowe and William Alazawi to discuss the dynamic challenges of using FibroScan and ot...

Send us Fan Mail In Season 3, Episode 6 , Roger Green assembles audio clips from Surfing the NASH Tsunami’s coverage of NASH-TAG 2022 to reveal an evolving view of the role combination therapies will play in the treatment and management of NASH patients. Discussion about “combination therapies” typically focuses on the idea of multiple agents prescribed concurrently to address a medical condition...

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. This conversation explores the single unsuccessful trial result accompanying the spate of positive reports. Intercept’s REVERSE study focuses on evaluating the safety and efficacy of obeticholic acid (OCA) in patients with compensated cirrhosis. Stephen...

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, the panel continues exploring oral drugs (specifically PXL-065) before reviewing positive interim data from the Phase 2b EMMPACT study by Axcella .  Roger Green notes that introducing multiple modes of action to the market will cre...

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Stephen Harrison continues his review of Phase 2B results from Akero’s HARMONY Trial before introducing more positive Phase 2B results from a study by Poxel . Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green shar...

Send us Fan Mail A recent string of press releases presaged some of the most exciting, promising data of the last decade in NASH drug development. In this conversation, Principal Investigator Stephen Harrison reviews Phase 2b results from Akero’s HARMONY Trial . Special guest Mazen Noureddin joins Jörn Schattenberg, Louise Campbell and Roger Green to share impressions.  This conversation starts wi...